ES2208884T3 - Soluciones mejoradas de agentes de contraste para la administracion intravasal. - Google Patents

Soluciones mejoradas de agentes de contraste para la administracion intravasal.

Info

Publication number
ES2208884T3
ES2208884T3 ES97914098T ES97914098T ES2208884T3 ES 2208884 T3 ES2208884 T3 ES 2208884T3 ES 97914098 T ES97914098 T ES 97914098T ES 97914098 T ES97914098 T ES 97914098T ES 2208884 T3 ES2208884 T3 ES 2208884T3
Authority
ES
Spain
Prior art keywords
solutions
additives
substances
reactions
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97914098T
Other languages
English (en)
Spanish (es)
Inventor
Ulrich Speck
Gabriele Schuhmann-Giampieri
Peter Muschick
Werner Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2208884T3 publication Critical patent/ES2208884T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES97914098T 1996-01-25 1997-01-27 Soluciones mejoradas de agentes de contraste para la administracion intravasal. Expired - Lifetime ES2208884T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095 1996-01-25
DE19604095 1996-01-25

Publications (1)

Publication Number Publication Date
ES2208884T3 true ES2208884T3 (es) 2004-06-16

Family

ID=7784538

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97914098T Expired - Lifetime ES2208884T3 (es) 1996-01-25 1997-01-27 Soluciones mejoradas de agentes de contraste para la administracion intravasal.

Country Status (21)

Country Link
US (1) US6638913B1 (enExample)
EP (1) EP0876140B1 (enExample)
JP (1) JP2000505789A (enExample)
KR (1) KR100505772B1 (enExample)
CN (1) CN1209751A (enExample)
AT (1) ATE251893T1 (enExample)
AU (1) AU2150497A (enExample)
BG (1) BG62913B1 (enExample)
BR (1) BR9707081A (enExample)
CA (1) CA2244209C (enExample)
CZ (1) CZ234898A3 (enExample)
DE (2) DE19703816A1 (enExample)
DK (1) DK0876140T3 (enExample)
ES (1) ES2208884T3 (enExample)
HU (1) HUP9901355A3 (enExample)
IL (1) IL124676A0 (enExample)
NO (1) NO983438L (enExample)
PL (1) PL328199A1 (enExample)
PT (1) PT876140E (enExample)
SK (1) SK101398A3 (enExample)
WO (1) WO1997026862A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7419683B2 (en) 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
MXPA00009593A (es) 1998-04-01 2004-03-10 Nortran Pharmaceuticals Inc Compuestos de eter aminociclohexilico y sus usos.
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
NZ543921A (en) 2003-05-02 2008-11-28 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
JP5583325B2 (ja) 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
TW201039854A (en) 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6351639B2 (ja) 2013-03-11 2018-07-04 エンドマグネティクス リミテッド リンパ節検出のための低浸透圧溶液
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
CN105579069A (zh) * 2013-03-27 2016-05-11 通用电气医疗集团股份有限公司 用于制备诊断组合物的方法和试剂
CA2988065C (en) 2015-06-04 2024-03-26 Endomagnetics Ltd. Marker materials and forms for magnetic marker localization (mml)
CA3097061A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754523A (fr) * 1969-08-06 1971-02-08 Beecham Group Ltd Vaccins
ZA793313B (en) * 1978-07-04 1980-08-27 Nyegaard & Co As A process for the preparation of a sterile injectable physiologically acceptable solution of an x-ray contrast agent and solutions of the x-ray contrast agent and a buffer
WO1982003773A1 (en) * 1981-04-27 1982-11-11 Baxter Travenol Lab Dialysis solution containing glucose,amino acids & insulin
WO1986000227A1 (en) * 1984-06-22 1986-01-16 Veech Richard L Electrolyte solutions and in vivo use thereof
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DK0437662T3 (da) 1990-01-18 1994-10-17 Cereria Amos Sgarbi Spa Gravlys
GB9020091D0 (en) * 1990-09-14 1990-10-24 Nycomed As Contrast media
DE4135193C1 (enExample) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
IT1256248B (it) * 1992-12-24 1995-11-29 Bracco Spa Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Also Published As

Publication number Publication date
PT876140E (pt) 2004-02-27
AU2150497A (en) 1997-08-20
NO983438D0 (no) 1998-07-24
CA2244209C (en) 2007-10-23
WO1997026862A2 (de) 1997-07-31
DE19703816A1 (de) 1997-08-07
HUP9901355A3 (en) 2000-06-28
CZ234898A3 (cs) 1998-11-11
SK101398A3 (en) 1998-12-02
NO983438L (no) 1998-09-18
BG102644A (en) 1999-06-30
DK0876140T3 (da) 2003-12-15
EP0876140A2 (de) 1998-11-11
CN1209751A (zh) 1999-03-03
CA2244209A1 (en) 1997-07-31
IL124676A0 (en) 1998-12-06
KR100505772B1 (ko) 2005-10-25
BG62913B1 (bg) 2000-11-30
PL328199A1 (en) 1999-01-18
US6638913B1 (en) 2003-10-28
ATE251893T1 (de) 2003-11-15
KR19990081979A (ko) 1999-11-15
BR9707081A (pt) 1999-05-25
WO1997026862A3 (de) 1997-10-23
JP2000505789A (ja) 2000-05-16
EP0876140B1 (de) 2003-10-15
HUP9901355A2 (hu) 1999-08-30
DE59710863D1 (de) 2003-11-20

Similar Documents

Publication Publication Date Title
ES2208884T3 (es) Soluciones mejoradas de agentes de contraste para la administracion intravasal.
ES2264274T5 (es) Composiciones antimicrobianas que comprenden taurolidina, ácido cítrico y citrato sódico
ES2264713T3 (es) Formulaciones de insulina estables.
US6548079B1 (en) Moxifloxacin formulation containing common salt
ES2854874T3 (es) Composiciones de magnesio para modular la farmacocinética y farmacodinamia de la insulina y dolor en el sitio de inyección
ES2218652T3 (es) Composiciones que comprenden pvp cuyo peso molecular medio es del orden de 7.000 a 12.000 daltons.
ES2253774T3 (es) Formulacion farmaceutica conteniendo hormona de crecimiento humana, histidina y un detergente no ionico.
ES2229693T3 (es) Formulaciones de co-disolventes que contienen vitamina d.
PT1988913E (pt) Formulação líquida de g-csf
ES2664951T5 (es) Composiciones que comprenden glicosaminoglicanos de baja viscosidad y uso de dicha composición en terapia de cistitis crónica
BRPI0719821B1 (pt) composição estável na armazenagem apropriada para administração a pacientes
US6150331A (en) Human growth hormone-containing aqueous pharmaceutical composition
JPH0714882B2 (ja) 循環器系ショックに対する高浸透圧等塩素性製剤
ES2383691T3 (es) Formulación líquida estable de hormonas de crecimiento
JP2012167132A (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤
UA73954C2 (uk) Водний розчин для внутрішньовенного введення та фармацевтичний розчин, що містять левосимендан
ES2385888T3 (es) Solución acuosa estable de eritropoyetina humana que no contiene albúmina sérica
ES2728071T3 (es) Composiciones oftalmológicas y su uso
US10238717B2 (en) Parenteral glucagon formulations
ES2415354T3 (es) Paracetamol para administración por vía parenteral
ES2323374T3 (es) Composicion farmaceutica de vinflunina destinada a la administracion parenteral, su procedimiento de preparacion y su uso.
JP3552240B2 (ja) 高濃度ｔｃｆ製剤
EP0124018B1 (en) Pharmaceutical preparation containing purified fibronectin
ES2311463T3 (es) Pomada oftalmica que comprende hidrocloruro de vancomicina para tratar enfermedades infecciosas oculares.
BRPI0621528A2 (pt) composição farmacêutica contendo lactato e cálcio, e usos da mesma